HO1 Stock Overview
Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$73.50 |
| 52 Week High | US$74.50 |
| 52 Week Low | US$66.50 |
| Beta | 0.99 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 11.97% |
| 5 Year Change | 64.06% |
| Change since IPO | 329.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| HO1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -3.7% | -0.5% |
| 1Y | n/a | -4.2% | 8.3% |
Return vs Industry: Insufficient data to determine how HO1 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how HO1 performed against the German Market.
Price Volatility
| HO1 volatility | |
|---|---|
| HO1 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HO1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine HO1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 6,990 | Steve MacMillan | www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| HO1 fundamental statistics | |
|---|---|
| Market cap | €17.34b |
| Earnings (TTM) | €666.35m |
| Revenue (TTM) | €3.79b |
26.0x
P/E Ratio4.6x
P/S RatioIs HO1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HO1 income statement (TTM) | |
|---|---|
| Revenue | US$3.99b |
| Cost of Revenue | US$1.57b |
| Gross Profit | US$2.42b |
| Other Expenses | US$1.71b |
| Earnings | US$701.50m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.02 |
| Gross Margin | 60.58% |
| Net Profit Margin | 17.59% |
| Debt/Equity Ratio | 51.4% |
How did HO1 perform over the long term?
See historical performance and comparison